Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Published 2012 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 13, Issue 3, Pages 239-246

Publisher

Elsevier BV

Online

2012-01-30

DOI

10.1016/s1470-2045(11)70393-x

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Ask a Question. Answer a Question.